Heather Frohman

Heather Frohman

Auto-generated profile, based on publicly available information

Heather Frohman

Department of Surgery, University of Kentucky Medical Center, Lexington, Kentucky

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in The Journal of Pain
Verified
Journal Article
Closed access
JBJeffrey J. Borckardt
Jeffrey J. Borckardt
MBMarom Bikson
Marom Bikson
HFHeather Frohman
Heather Frohman
SRScott T. Reeves
Scott T. Reeves
ADAbhishek Datta
Abhishek Datta
MGMark S. George
Mark S. George

1 June 2011 in Appetite
Verified
Journal Article
Closed access
RGRachel L. Goldman
Rachel L. Goldman
JBJeffrey J. Borckardt
Jeffrey J. Borckardt
HFHeather A. Frohman
Heather A. Frohman
POPatrick M. O’neil
Patrick M. O’neil
AMAlok Madan
Alok Madan
MGMark S. George
Mark S. George

1 November 2011 in Pain
Verified
Journal Article
Closed access
ESEdward Baron Short
Edward Baron Short
JBJeffrey J. Borckardt
Jeffrey J. Borckardt
BABerry S. Anderson
Berry S. Anderson
HFHeather Frohman
Heather Frohman
WBWilliam Beam
William Beam
MGMark S. George
Mark S. George
Transcranial magnetic stimulation (TMS) of the prefrontal cortex can cause changes in acute pain perception. Several weeks of daily left prefrontal TMS has been shown to treat depression. We recruited 20 patients with fibromyalgia, defined by American College of Rheumatology criteria, and randomized them to receive 4000 pulses at 10 Hz TMS (n=10), or sham TMS (n=10) treatment for 10 sessions over 2 weeks along with their standard medications, which were fixed and stable for at least 4 weeks before starting sessions. Subjects recorded daily pain, mood, and activity. Blinded raters assessed pain, mood, functional status, and tender points weekly with the Brief Pain Inventory, Hamilton Depression Rating Scale, and Fibromyalgia Impact Questionnaire. No statistically significant differences between groups were observed. Patients who received active TMS had a mean 29% (statistically significant) reduction in pain symptoms in comparison to their baseline pain. Sham TMS participants had a 4% nonsignificant change in daily pain from their baseline pain. At 2 weeks after treatment, there was a significant improvement in depression symptoms in the active group compared to baseline. Pain reduction preceded antidepressant effects. TMS was well tolerated, with few side effects. Further studies that address study limitations are needed to determine whether daily prefrontal TMS may be an effective, durable, and clinically useful treatment for fibromyalgia symptoms.

1 June 2011 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
JBJeffrey J. Borckardt
Jeffrey J. Borckardt
JRJoseph Romagnuolo
Joseph Romagnuolo
SRScott T. Reeves
Scott T. Reeves
AMAlok Madan
Alok Madan
HFHeather Frohman
Heather Frohman
MGMark S. George
Mark S. George

1 July 2013 in Pain Medicine
Verified
Journal Article
Open access
PDF file
LMLaura Martin
Laura Martin
JBJeffrey J. Borckardt
Jeffrey J. Borckardt
SRScott T. Reeves
Scott T. Reeves
HFHeather Frohman
Heather Frohman
WBWill Beam
Will Beam
MGMark George
Mark George
Objective.. Repetitive transcranial magnetic stimulation (rTMS) has been shown to effectively treat depression, and its potential value in pain managem

1 April 2012 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
ARAlexander S. Rosemurgy
Alexander S. Rosemurgy
HFHeather A. Frohman
Heather A. Frohman
ATAnthony F. Teta
Anthony F. Teta
KLKenneth Luberice
Kenneth Luberice
SRSharona B. Ross
Sharona B. Ross
Widespread application of transjugular intrahepatic portasystemic shunt (TIPS) continues despite the lack of trials documenting efficacy superior to surgical shunting. Here we present an 18-year follow-up of a prospective randomized trial comparing TIPS with small-diameter prosthetic H-graft portacaval shunt (HGPCS) for portal decompression. Beginning in 1993, patients were prospectively randomized to undergo either TIPS or HGPCS as definitive therapy for portal hypertension due to cirrhosis. Complications of shunting and long-term outcomes were noted. Failure of shunting was prospectively defined as the inability to place shunt, irreversible shunt occlusion, major variceal rehemorrhage, unanticipated liver transplantation, or death. Survival and shunt failure were compared using Kaplan-Meier curve analysis. Median data are reported. Patient presentation, circumstances of shunting, causes of cirrhosis, severity of hepatic dysfunction (eg, Child's class, Model for End-Stage Liver Disease score), and predicted survival after shunting did not differ between patients undergoing TIPS (n = 66) or HGPCS (n = 66). Survival was significantly longer after HGPCS for patients of Child's class A (91 vs 19 months; p = 0.009) or class B (63 vs 21 months; p = 0.02). Shunt failure occurred later after HGPCS than TIPS (45 vs 22 months; p = 0.04). Compared with TIPS, survival after HGPCS was superior for patients with better liver function (eg, Child's class A or B). Shunt failure after HGPCS occurred later than after TIPS. Rather than TIPS, application of HGPCS is preferred for patients with complicated cirrhosis and better hepatic function.